Cost-effectiveness of hypertension treatment

Clinical and Experimental Hypertension

Volumn 18, Issue 3-4, 1996, Pages 399-413

  Ménard, Joël ^a  

^a HÔPITAL BROUSSAIS   (France)

Author keywords

cost effectiveness; diagnosis; hypertension; treatment

Indexed keywords

ANTIHYPERTENSIVE AGENT;

AGE; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; HUMAN; HYPERTENSION; LIFE EXPECTANCY; RISK FACTOR;

EID: 0029984477     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.3109/10641969609088972     Document Type: Conference Paper

References (77)

1. Whelton, P., Brancati, F. Hypertension management in populations. Clin. Exper. Hypertension 1993;15:1147-1156.
2. Trenkwalder, P., Ruland, D., Stender, M., Gebhard, J., Trenkwalder, C., Lydtin, H., Hense, H. Prevalence, awareness, treatment and control of hypertension in a population over the age of 65 years : results from the Starnberg study on epidemiology of parkinsonism and hypertension in the elderly (STEPHY). J. Hypertension 1994;6:709-716.
3. Vaisse, B., Renucci, J., Quilichini, J., et al. Efficacy of antihypertensive treatment in the French population. Am. J. Hypertension 1994;119 A:I 82 (Abstr.).
4. Weinstein, M., Stason, W. Hypertension: a policy perspective. Harvard University Press 1976
5. Bulpitt, C., Fletcher, A. Cost-effectiveness of the treatment of hypertension. Clin. Exp. Hypertension 1993;15:1131-1146.
6. Fletcher, A. Pressure to treat and pressure to cost : a review of cost-effectiveness analysis. J. Hypertension 1991;9:193-198.
7. Fletcher, A., Bulpitt, C. Pharmacoeconomic evaluation of risk factors for cardiovascular disease. An epidemiological prospective. Pharmaco-Enonomics 1992;1:33-44.
8. Johannesson, M., Jonsson, B. A review of cost-effectiveness analyses of Hypertension treatment. PharmacoEconomics 1992;1:250-264.
9. Johannesson, M., Jönsson, B. Cost-effectiveness analysis of hypertension treatment. A review of methodological issues. Health Policy. 1991;19:55-78.
10. Johannesson, M., Dahlöf, B., Lindholm, L., et al. The cost-effectiveness of treating hypertension in elderly people - an analysis of the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). J. Intern. Med. 1993;234:317-323.
11. Johannesson, M. The impact of age on the cost-effectiveness of hypertension treatment. An analysis of randomized drug trials. Med. Decis. Making 1994;14:236-244.
12. Johannesson, M., Hedbrant, J., Jönsson, B. A computer simulation for cost-effectiveness analysis of cardiovascular disease prevention. Med. Inform. 1991;16:355-362.
13. Johannesson, M. The cost-effectiveness of hypertension treatment in Sweeden. Phamacoeconomics, 1995;7:242-250.
14. Chambless, L., Dobson, A., Patterson, C., Raines, B. On the use of a logistic risk score in predicting risk of coronary heart disease. Statistics in Medicine 1990;9:385-396.
15. Gordon, T., Garcia-Palmieri, M., Kagan, A., Kannel, W., Schiffman, J. Differences in CHD in Framingham, Honolulu and Puerto-Rico. J. Chron. Dis. 1974;27:329-344.
16. Leaverton, P., Sorlie, P., Kleinman, J., et al. Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study. J. Chron. Dis. 1987;40:775-784.
17. Medical Research Council Working Party. MRC trial of treatment of hypertension in older adults: principal results. Br. Med. J. 1992;304:405-412.
18. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA 1991;265:2355-3264.
19. Dahlöf, B., Lindholm, L., Hansson, L., et al. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP Hypertension). Lancet 1991;338:1281-1285.
20. Kawachi, I., Malcom, L. The cost-effectiveness of treating mild-to-moderate hypertension : a reappraisal. J. Hypertension 1991;9:199-208.
21. MacMahon, S., Rodgers, A. The effects of blood pressure reduction in older patients: an overview of five randomized controlled trials in elderly hypertension. Clin. Exper. Hypertension 1993;15:967-978.
22. Cruickshank, J., Thorp, J., Zacharias, F. Benefits and potential harm of lowering high blood pressure. Lancet 1987;1:581-584.
23. Fifth Report on the Joint National Committee Report on detection, evaluation and treatment of high blood pressure. Arch. Intern. Med. 1993;153:154-184.
24. Memorandum from a WHO/ISH Meeting. Guidelines for management of mild hypertension. Clin. Exper. Hypertension 1993;15:1363-1395.
25. Moser, M. Suppositions and speculations : their possible effects on treatment decisions in the management of hypertension. Am. Heart. J. 1989;118:1362-1369.
26. Hampton, J. Secondary prevention of acute myocardial infarction with beta-blocking agents and calcium antagonists. Am. J. Cardiol. 1990;66:3C-8C.
27. Simoons, M. Myocardial infarction: ACE inhibitors for all? for ever? Lancet 1994;344:279-281.
28. Goldbourt, U., Behar, S., Reicher-Reiss, H., Zion, M., Mandelzweig, L., Kaplinsky, E. Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch. Intern. Med. 1993;153:345-353.
29. Yusuf, S., Held, P., Furberg, C. Update of effects of calcium antagonists in myocardial infarction or angina in light of the Second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. Am. J. Cardiol. 1991;67:1295-1297.
30. Croog, S., Levine, S., Testa, M., Brown, B., Bulpitt, C., Jenkins, C., Klerman, G., Williams, G. The effects of antihypertensive therapy on quality of life. N. Engl. J. Med. 1986;314:1657-1664.
31. Fletcher, A., Chester, P., Hawkins, C., Latham, A., Pyke, L., Bulpitt, C. The effects of verapamil and propanolol on quality of life in hypertension. J. Hum. Hypertension 1989;3:125-130.
32. Alderman, M., Lamport, B. Labelling hypertensives, a review of the data. J. Clin. Epidemiol. 1990;43:195-200.
33. Hjemdahl, P., Wiklund, I. Quality of life on antihypertensive drug therapy: scientific end-point or marketing. J. Hypertension 1992;10:1437-1446.
34. Testa, M., Anderson, R., Nackley, J., Hollenberg, N., and the Quality-of-life hypertension study group. Quality of life and antihypertensive therapy in men. A comparison of Captopril and Enalapril. N. Engl. J. Med. 1993;328:907-913.
35. Johannesson, M. On the discounting of gained life-years in cost-effectiveness analysis. Int. J. Technol. Assess. 1992;8:359-364.
36. Rose, G., Shipley, M. Effects of coronary risk reduction of the pattern of mortality. Lancet 1990;335:275-277.
37. Strasser, T. Relative costs of antihypertensive drug treatment. J. Human Hypertension 1992;6:489-494.
38. Stason, W. Opportunities to improve the cost-effectiveness of treatment for hypertension. Hypertension 1991;18(Suppl. I):I-161-I-166.
39. Ménard, J. Oil and water? Economic advantage and biomedical progress do not mix well in a Government Guidelines Committee. Am. J. Hypertens. 1994;7:877-885.
40. Johannesson, M., Fagerberg, B. A health-economic comparison of diet and drug treatment in obese men with mild hypertension. J. Hypertension 1992;10:1063-1070.
41. Johannesson, M. The cost-effectiveness of the switch towards more expensive antihypertensive drugs. Health Policy. 1994;28:1-13.
42. Strasser, T., Wilhelmsen, L. The Hypertension Management Audit Project Group. Does hypertension management audit provide clues for cost containment ? J. Human Hypertension 1992;6:485-488.
43. Abe, H., Yokouchi, M., Nagata, S., Askida, T., et al. Relation of office and home blood pressure to left ventricular hypertrophy and performance in patients with hypertension. High Blood Pressure 1992;1:279-285.
44. James, J., Pickering, T., Yee, L., et al. The reproducibility of average ambulatory, home and clinic pressures. Hypertension 1988;11:545-549.
45. Devereux, R., de Simone, G., Ganau, A., et al. Left ventricular hypertrophy and hypertension. Clin. and Exper. Hypertension 1993;15:1025-1032.
46. Appel, L., Stason, W. Ambulatory blood pressure monitoring and blood pressure self-measurement in the diagnosis and magagement of hypertension. Ann. Intern. Med. 1993;118:867-882.
47. Mejia, A., Julius, S., Jones, K., Schork, N., Kneisley, J. The Tecumseh blood pressure study. Normative data on blood pressure self determination. Arch. Intern. Med. 1990;150:1209-1213.
48. Imai, Y., Satoh, H., Nagai, K., et al. Characteristics of a community-based distribution of home blood pressure in ohasama in northern Japan. J. Hypertension 1993;11:1441-1449.
49. de Gaudemaris, R., Chau, N., Mallion, J. for the Groupe de la Mesure, French Society of Hypertension. Home blood pressure: variability, comparison with office readings and proposal for reference values. J. Hypertension 1994;12:831-839.
50. Sega, G., Bravi, C., Cesana, G., Valagussa, F., Mancia, G., Zanchetti, A. Ambulatory and home blood pressure normality. The Pamela Study 1994;23((Suppl. 5)):S12-S15.
51. Staessen, J., Fagard, R., Lijsen, P., Thijs, L., Van Hoof, R., Amery, A. The mean and range of the ambulatory blood pressure in normotensive subjects from a meter-analysis of 23 studies. Am. J. Cardiol. 1991;67:723-727.
52. Staessen, J., Fagard, R., Lijnen, P., Thijs, L., Van Hulle, S., Vyncke, G., Amery, A. Ambulatory blood pressure and blood pressure measured at home : progress report on a population study. J. Cardiovasc. Pharmacol. 1994;23(Suppl. 5):S5-S11.
53. Kuyck, W., Van, M., GA, Grobbee, D. Home measurement with confidence: distribution of self-recorded blood pressure in normotensive subjects. High Blood Pressure 1993;2:291-298.
54. Gradman, A., Pangan, P., Germain, M. Lack of correlation between clinic and 24 hour ambulatory blood pressure in subjects participating in a therapeutic drug trial. J. Clin. Epidemiol. 1990;42:1049-1054.
55. Gould, B., Hornung, R., Kieso, H., Cashman, P., Raftery, E. An evaluation of self-recorded blood pressure during drug trials. Hypertension 1986;8:267-271.
56. Jeunemaitre, X., Ged, E., Ducrocq, M., Alhenc-Gélas, F., Corvol, P., Ménard, J. Effects of transdernal clonidine in young and elderly patients with mild hypertension: evaluation by three non invasive methods of blood pressure measurement. J. Cardiovasc. Pharmacol. 1987;10:162-167.
57. Porchet, M., Bussen, J., Waeber, B., Nussberger, J., Brunner, H. Unpredictability of blood pressures recorded outside the clinic in the treated hypertensive patient. J. Cardiovasc. Pharmacol. 1986;8:332-335.
58. Krakoff, L. Ambulatory blood pressure monitoring can improve cost-effective management of hypertension. Am. J. Hypertension 1993;6:220S-224S.
59. Schaub, A., Steiner, A., Vetter, W. Compliance to treatment. Clin. Exper. Hypertension 1993;15:1121-1130.
60. Soghikian, K., Casper, S., Fireman, B., Hunkeler, E., Hurley, L., tekawa, I., Vogt, T. Home blood pressure monitoring-effect on use of medical services and medical care costs. Med. Care 1992;30:855-867.
61. Yarows, S., Khoury, S., Sowers, J. Cost effectiveness of 24-hour ambulatory blood pressure monitoring in evaluation and treatment of essential hypertension. Am. J. Hypertension 1994;7:464-468.
62. Elijovich, F., Laffer, C. Bayesian analysis supports use of ambulatory blood pressure monitors for screening. Hypertension 1992;19(Suppl. II):II-268-II-272.
63. Littenberg, B., Garber, A., Sox, H. Screening for hypertension. Ann. Intern. Med. 1990;112:192-202.
64. Fagard, R., Bielen, E., Staessen, J., Thijs, L., Amery, A. Response of ambulatory blood pressure to antihypertensive therapy guided by clinic blood pressure. Am. J. Hypertension Am. J. Hypertension;6:648-653.
65. Waeber, B., Pertillo, A., Nussberger, J., et al. Are some hypertensive patients overtreated ? A prospective study of ambulatory blood pressure recording. Lancet 1985;ii(732-734).
66. Devereux, R. The value of non invasive measurements in hypertension. JAMA 1990;264:2798-2799.
67. Eagle, K., Blank, D., Aguiar, E., Firth, L. Economic impact of regression of left ventricular hypertrophy by antihypertensive drugs. J. Hum. Hypertension 1993;7:341-351.
68. Devereux, R. Angiotensin converting enzyme inhibition and regression of hypertensive left ventricular hypertrophy. Churchill Livingstone, Edinburgh: 1991, pp43-51.
69. Wolf, P., Kannel, W., Sorlie, P., Me Namara, P. Asymptomatic carotid bruit and the risk of stroke. JAMA 1981;245:1442-1445.
70. Mégnien, J., Sene, V., Jeannin, S., et al. Coronary calcification and its relation to extracoronary athrosclerosis in asymptomatic hypercholesterolemic men. Circulation 1992;85:1799-1807.
71. Epstein, A., Begg, C., Me Neil, B. The effect of group size on test ordering for hypertensive patients. N. Engl. J. Med. 1983;309:464-468.
72. Gallup, G. J., Cotugno, H. Preferences and practices of Americans and their physicians in antihypertensive therapy. Am. J. Med. 1986;81:3-8.
73. Alderman, M. Blood pressure management: individualized treatment based on absolute risk and the potential for benefit. Ann. Intern. Med. 1993;119:329-335.
74. Levy, D. A multifactorial approach to coronary disease risk assessment. Clin. Exper. Hypertension 1993;15:1077-1086.
75. The HOT Study Group. The hypertension optimal treatment study (the HOTStudy). Blood Pressure 1993;2:62-68.
76. Isles, C., Walker, L., Beevers, G., et al. Mortality in patients of the Glasgow Blood Pressure Clinic. J. Hypertension 1986;4:141-156.
77. Mc Clellan, W., Hall, W., Brogan, D., Miles, C., Wilber, J. Continuity of care in hypertension. An important correlate of blood pressure control among aware hypertensives. Arch. Intern. Med. 1988;148:525-528.